ANN ARBOR, MI / ACCESSWIRE / April 24, 2019 / ENDRA Life Sciences Inc. (''ENDRA'') (NDRA), a developer of enhanced ultrasound technologies, will hold a conference call on Tuesday, May 14, 2019 at 4:30 p.m. Eastern time to discuss its results for the first quarter ended March 31, 2019. Financial results will be issued in a press release prior to the call.
ENDRA CEO Francois Michelon, CFO David Wells and CTO Michael Thornton will host the conference call, followed by a question and answer period.
To access the call, please use the following information:
Tuesday, May 14, 2019
4:30 p.m. ET, 1:30 p.m. PT
Toll-free dial-in number:
International dial-in number:
Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact MZ Group at 1-949-491-8235.
The conference call will be broadcast live and available for replay at https://www.investornetwork.com/event/presentation/47141 and via the investor relations section of the Company's website at www.endrainc.com.
A replay of the conference call will be available after 7:30 p.m. Eastern time through May 28, 2019.
|Toll-free replay number:|| |
International replay number:
About ENDRA Life Sciences Inc.
ENDRA Life Sciences Inc. (''ENDRA'') (NDRA) is a developer of enhanced ultrasound technologies. ENDRA is developing a next generation Thermo-Acoustic Enhanced UltraSound (TAEUS™) platform to enable clinicians to visualize human tissue composition, function and temperature in ways previously possible only with CT & MRI - at a fraction of the cost, and at the point-of-care. ENDRA's first TAEUS application will focus on the fatty liver tissue characterization, for early detection and monitoring of Non-Alcoholic Fatty Liver Disease (NAFLD). ENDRA's goal is to bring new capabilities to ultrasound - thereby broadening access to better healthcare. For more information, please visit www.endrainc.com.
About Non-Alcoholic Fatty Liver Disease (NAFLD)
NAFLD is a condition closely associated with obesity, diabetes, hepatitis-C and certain genetic predispositions in which fat accumulates in the liver. NAFLD affects over 1 billion people globally and is estimated to cost the U.S healthcare system over $100 billion annually. NAFLD is often asymptomatic and if left untreated, NAFLD can progress to inflammation (NASH), tissue scarring (fibrosis), cell death (cirrhosis) and liver cancer. By 2025, NAFLD is forecast to be the greatest root cause of liver transplants. The only tools currently available for diagnosing and monitoring NAFLD are impractical: expensive Magnetic Resonance Imaging (MRI) or an invasive surgical biopsy.
SOURCE: ENDRA Life Sciences Inc.
View source version on accesswire.com: